Immunization Provider Memos and Communications

This email is to inform you that the North Carolina Immunization Program (NCIP) has opened applications for birthing hospitals interested in participating in the replacement model for birth dose Hepatitis B and RSV.

The purpose of this email is to inform VFC-enrolled providers that the RSV monoclonal antibody product clesrovimab (trade name ENFLONSIA™ manufactured by Merck) is now available for ordering. VFC doses will begin shipping after Oct. 2, 2025.

Download The 2025 LHD Annual Immunization Assessment Memo

Dear Local Health Department Partner,

Dear Local Health Departments,

On Wednesday, Aug. 27, 2025, FDA approved the updated 2025-2026 COVID-19 vaccines and rescinded Emergency Use Authorizations (EUA) for previously authorized COVID-19 vaccines.

Dear Providers,

On Wednesday, Aug. 27, 2025, FDA approved the updated 2025-2026 COVID-19 vaccines and rescinded Emergency Use Authorizations (EUA) for previously authorized COVID-19 vaccines.

Dear Local Health Department Partner,

This memo is to inform North Carolina Immunization Program (NCIP) providers of the availability of influenza vaccine and the ordering process for the 2025-2026 respiratory season. Please take time to carefully review this memo in full.